MPM Capital Announces Novartis International Global Head M&A and Licensing Anthony Rosenberg to Join as Managing Director

BOSTON--MPM Capital today announces the appointment of long-time Novartis M&A and Licensing executive Anthony (Tony) Rosenberg as Managing Director, effective immediately. Tony will serve as a strategic advisor and board member to MPM portfolio companies, advancing MPM's proven strategy of identifying promising assets and assembling teams to build commercially successful companies.

"Tony brings unique expertise to MPM Capital investments across our portfolio that will further our mission to build leading life sciences firms developing breakthrough products," said Ansbert K. Gadicke, MPM Capital Managing Director and co-founder.

"With his proven track record in global M&A, experience across pharma and biotech, and knowledge of both MPM management and portfolio, Tony brings tremendous value to our work and we our pleased to have him join our team," Gadicke said.

Since 2013, Tony has served as Global Head, M&A and Licensing (Corporate) for Novartis, based in Basel, Switzerland. In this role Tony oversaw the Novartis portfolio transformation, a comprehensive set of transactions announced last spring, to focus the company on its global businesses in innovative pharmaceuticals, eye care and generics. Tony is also a current Board member at Radius and former board member at Idenix, both of which are MPM investments.

Tony joined Novartis predecessor company Sandoz in the U.K. in 1980, where he held diverse leadership positions across sales and marketing, business development and strategic planning. He moved to Basel in 1994, assuming roles of increasing responsibility, and in 2000 was appointed Global Head of the Transplantation and Immunology Business Unit. In 2005, Tony was appointed Global Head of Business Development and Licensing (Pharma), and managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group.

Tony has a Bachelor of Science degree in Biological Sciences from the University of Leicester and a Masters of Science in Physiology from the University of London. He is an avid football player and fan.

About MPM Capital -- MPM Capital is a global leader in early-stage life sciences venture investing with a track-record of success in building world-class companies around transformational treatments and cures. With its deep experience, dedicated team of operating executives and distinguished MSAB, MPM Capital is powering medical breakthroughs that change lives.



MPM Capital
Michele Galen +1-201-400-4945
[email protected]
Sarah Reed: +1-781-697-4502
[email protected]


Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.